Clinical Trial Update: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

View source ↗

Summary

Ongoing ERASE II trial in China recruits adults with bronchiectasis to assess long-term impact of inhaled tobramycin on eradication of Pseudomonas aeruginosa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• TOBI (tobramycin) inhalation solution (tobramycin)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Bronchiectasis Adult | Status: RECRUITING